Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A new class of drugs has become a phenomenon. GLP-1 receptor agonists, originally developed to treat type 2 diabetes, are now ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Aardvark has made significant progress across our pipeline, and we are well-positioned to unlock the full potential of ARD-101 and ARD-201 across ...

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

In a groundbreaking study, scientists have identified a gut microbe, Bacteroides vulgatus, and its metabolites as potential ...

WEIGHT loss drugs are still being brazenly flogged on the black market by a celebrity hairdresser who gave The Sun a Mounjaro ...

A number of young adults and adolescents who are eligible for GLP-1 receptor agonists were not currently insured.

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...